106 related articles for article (PubMed ID: 1546720)
1. Hypercalcemia in idiopathic myelofibrosis: modulation of calcium and collagen homeostasis by 1,25-dihydroxyvitamin D3.
Voss A; Schmidt K; Hasselbalch H; Junker P
Am J Hematol; 1992 Mar; 39(3):231-3. PubMed ID: 1546720
[TBL] [Abstract][Full Text] [Related]
2. Resorptive hypercalcemia in post-essential thrombocythemia myelofibrosis: treatment with denosumab.
Khoury N; Chang J; Gru AA; Whyte MP
J Clin Endocrinol Metab; 2012 Sep; 97(9):3051-5. PubMed ID: 22730513
[TBL] [Abstract][Full Text] [Related]
3. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
Lee SH; Huang TS; Hsieh SJ
Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
[TBL] [Abstract][Full Text] [Related]
4. A role for 1,25-dihydroxyvitamin D3 in control of bone-marrow collagen deposition?
McCarthy DM; Hibbin JA; Goldman JM
Lancet; 1984 Jan; 1(8368):78-80. PubMed ID: 6140427
[TBL] [Abstract][Full Text] [Related]
5. 1,25-dihydroxyvitamin D3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hypercalcemic rats with continuous parathyroid hormone-related peptide infusion.
Endo K; Katsumata K; Hirata M; Masaki T; Kubodera N; Nakamura T; Ikeda K; Ogata E
J Bone Miner Res; 2000 Jan; 15(1):175-81. PubMed ID: 10646127
[TBL] [Abstract][Full Text] [Related]
6. [Is 1,25(OH)2D3 effective in chronic osteomyelofibrosis?].
Eugster C; Brun del Re GP; Bucher U
Schweiz Med Wochenschr; 1986 Dec; 116(50):1767-70. PubMed ID: 3798067
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Diehl V
Leuk Lymphoma; 2003 Jun; 44(6):949-53. PubMed ID: 12854892
[TBL] [Abstract][Full Text] [Related]
8. A cross-sectional study on biochemical parameters of bone turnover and vitamin d metabolites in healthy dutch children and young adults.
van der Sluis IM; Hop WC; van Leeuwen JP; Pols HA; de Muinck Keizer-Schrama SM
Horm Res; 2002; 57(5-6):170-9. PubMed ID: 12053089
[TBL] [Abstract][Full Text] [Related]
9. Hypercalcemia and elevated serum 1,25-dihydroxyvitamin D3 in a patient with Hodgkin's lymphoma.
Schaefer K; Saupe J; Pauls A; von Herrath D
Klin Wochenschr; 1986 Jan; 64(2):89-91. PubMed ID: 3754025
[TBL] [Abstract][Full Text] [Related]
10. Relationship of plasma bone cytokines with hypercalcemia in cancer patients.
Motellón JL; Jiménez FJ; de Miguel F; Jaras MJ; Díaz A; Hurtado J; Esbrit P
Clin Chim Acta; 2000 Dec; 302(1-2):59-68. PubMed ID: 11074064
[TBL] [Abstract][Full Text] [Related]
11. Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites.
Schömig M; Ritz E
Nephrol Dial Transplant; 2000; 15 Suppl 5():18-24. PubMed ID: 11073270
[TBL] [Abstract][Full Text] [Related]
12. A sequential histological study of bone marrow fibrosis in idiopathic myelofibrosis.
Hasselbalch H; Lisse I
Eur J Haematol; 1991 May; 46(5):285-9. PubMed ID: 2044723
[TBL] [Abstract][Full Text] [Related]
13. [Serum levels of carboxyterminal propeptide of type I procollagen (PICP), cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) and carboxyterminal parathyroid hormone-related protein (C-PTHrP) in hematological malignancies with bone lesions and hypercalcemia].
Tanaka K; Shiraishi K; Sakamoto A; Jojima H; Masuchi K; Okubo Y; Tanaka M; Fuzimatsu Y; Fukahori S; Osabe S; Imamura Y; Honda J; Oizumi K
Rinsho Ketsueki; 1998 Apr; 39(4):273-80. PubMed ID: 9597894
[TBL] [Abstract][Full Text] [Related]
14. Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia.
Endo K; Katsumata K; Iguchi H; Kubodera N; Teramoto T; Ikeda K; Fujita T; Ogata E
J Bone Miner Res; 1998 Sep; 13(9):1378-83. PubMed ID: 9738509
[TBL] [Abstract][Full Text] [Related]
15. [The beneficial effect of 1,25-dihydroxycholecalciferol on the excess of blasts and the myelofibrosis in 2 cases of chronic myeloproliferative syndrome].
Raya Sánchez JM; Hernández Nieto L; Brito Barroso ML; Hernández García MT
Med Clin (Barc); 1994 Mar; 102(10):380-2. PubMed ID: 8182985
[TBL] [Abstract][Full Text] [Related]
16. Preliminary trials with 24,25-dihydroxyvitamin D3 in dialysis osteomalacia.
Hodsman AB; Wong EG; Sherrard DJ; Brickman AS; Lee DB; Singer FR; Norman AW; Coburn JW
Am J Med; 1983 Mar; 74(3):407-14. PubMed ID: 6338716
[TBL] [Abstract][Full Text] [Related]
17. Changes in bone turnover after parathyroidectomy in dialysis patients: role of calcitriol administration.
Mazzaferro S; Chicca S; Pasquali M; Zaraca F; Ballanti P; Taggi F; Coen G; Cinotti GA; Carboni M
Nephrol Dial Transplant; 2000 Jun; 15(6):877-82. PubMed ID: 10831645
[TBL] [Abstract][Full Text] [Related]
18. [Beneficial effect of 1,25-dihydroxyvitamin D3 in the treatment of myelofibrosis].
Palomera L; García Díez I; Martínez R
Med Clin (Barc); 1989 Sep; 93(7):265-8. PubMed ID: 2811498
[TBL] [Abstract][Full Text] [Related]
19. Acute myelofibrosis and malignant hypercalcemia.
Libnoch JA; Ajlouni K; Millman WL; Guansing AR; Theil GB
Am J Med; 1977 Mar; 62(3):432-8. PubMed ID: 842561
[TBL] [Abstract][Full Text] [Related]
20. Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis.
Thiele J; Kvasnicka HM; Schmitt-Gräff A; Hülsemann R; Diehl V
Histol Histopathol; 2004 Jan; 19(1):239-50. PubMed ID: 14702192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
